227 related articles for article (PubMed ID: 37256462)
1. Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.
Wei C; Fazal M; Loh A; Kapoor R; Gomez SE; Shah S; Rogers AJ; Narayan SM; Wang PJ; Witteles RM; Perino AC; Cheng P; Rhee JW; Baykaner T
J Interv Card Electrophysiol; 2024 Jan; 67(1):111-118. PubMed ID: 37256462
[TBL] [Abstract][Full Text] [Related]
2. Arrhythmia Patterns in Patients on Ibrutinib.
Fazal M; Kapoor R; Cheng P; Rogers AJ; Narayan SM; Wang P; Witteles RM; Perino AC; Baykaner T; Rhee JW
Front Cardiovasc Med; 2021; 8():792310. PubMed ID: 35047578
[No Abstract] [Full Text] [Related]
3. Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death.
Boriani G; Menna P; Morgagni R; Minotti G; Vitolo M
Chemotherapy; 2023; 68(2):61-72. PubMed ID: 36366814
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature.
Fazal M; Wei C; Chuy KL; Hussain K; Gomez SE; Ba SS; Pietrasik G; Yadav N; Ghazizadeh Z; Kapoor R; Witteles RM; Blackmon A; Wang PJ; John RM; Narayan SM; Cheng P; Rhee JW; Baykaner T
J Interv Card Electrophysiol; 2023 Aug; 66(5):1165-1175. PubMed ID: 36411365
[TBL] [Abstract][Full Text] [Related]
5. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors: Recent Updates.
Fares A; Carracedo Uribe C; Martinez D; Rehman T; Silva Rondon C; Sandoval-Sus J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396884
[TBL] [Abstract][Full Text] [Related]
8. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
10. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.
Ran F; Liu Y; Wang C; Xu Z; Zhang Y; Liu Y; Zhao G; Ling Y
Eur J Med Chem; 2022 Feb; 229():114009. PubMed ID: 34839996
[TBL] [Abstract][Full Text] [Related]
11. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
Front Immunol; 2019; 10():2129. PubMed ID: 31552054
[TBL] [Abstract][Full Text] [Related]
12. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.
Christensen BW; Zaha VG; Awan FT
Expert Rev Hematol; 2022 Apr; 15(4):321-331. PubMed ID: 35437106
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia:
Quartermaine C; Ghazi SM; Yasin A; Awan FT; Fradley M; Wiczer T; Kalathoor S; Ferdousi M; Krishan S; Habib A; Shaaban A; Kola-Kehinde O; Kittai AS; Rogers KA; Grever M; Ruz P; Bhat S; Dickerson T; Byrd JC; Woyach J; Addison D
JACC CardioOncol; 2023 Oct; 5(5):570-590. PubMed ID: 37969643
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
16. Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.
Xu B; Liang L; Jiang Y; Zhao Z
J Mol Graph Model; 2024 Jan; 126():108623. PubMed ID: 37716293
[TBL] [Abstract][Full Text] [Related]
17. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to Cryptococcus neoformans Infection with Bruton's Tyrosine Kinase Inhibition.
Messina JA; Giamberardino CD; Tenor JL; Toffaletti DL; Schell WA; Asfaw YG; Palmucci JR; Lionakis MS; Perfect JR
Infect Immun; 2023 Aug; 91(8):e0004223. PubMed ID: 37404186
[TBL] [Abstract][Full Text] [Related]
19. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Liu N; Hoogendoorn S; van de Kar B; Kaptein A; Barf T; Driessen C; Filippov DV; van der Marel GA; van der Stelt M; Overkleeft HS
Org Biomol Chem; 2015 May; 13(18):5147-57. PubMed ID: 25849561
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib.
Avalon JC; Fuqua J; Miller T; Deskins S; Wakefield C; King A; Inderbitzin-Brooks S; Bianco C; Veltri L; Fang W; Craig M; Kanate A; Ross K; Malla M; Patel B
Cardiooncology; 2021 Nov; 7(1):38. PubMed ID: 34798905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]